Generated September 26, 2026.
Overview
HIMS is a stock in a telehealth-and-pharmacy company that went public in September 2019. The comparison is between owning the underlying business directly versus a synthetic-income wrapper around it.
How they differ
The core difference is structure and income strategy. HIMS carries a 2.412, meaning it moves roughly 2.4 times as much as the broad market in either direction. HMYY's approach is to cap losses through the put-spread collar structure, though its own volatility profile is not reported.
Who each is best for
HIMS: Fits investors who hold conviction in telehealth-pharmacy secular growth, tolerate high market sensitivity, and have no need for current income from their healthcare allocation. Capital appreciation is the expected return source. Fits those who view synthetic income as an alternative to the underlying stock's zero yield.
Key risks to know
- NAV erosion at extreme yields. A 77.96% annualized payout on a $5.46 share price implies distributions that may outpace underlying HIMS price appreciation or returns over the fund's life. Whether payouts rely on capital return rather than underlying gains warrants investigation.
- Options assignment and forced stock holding. The put-spread collar structure can result in assignment of shares at the strike price if HIMS declines sharply. Investors expecting weekly distributions may instead receive stock, changing their position profile involuntarily.
- Leverage and volatility amplification. The fund sells spreads on leveraged proxies of HIMS, not on HIMS directly. During equity market stress, leveraged instruments amplify losses, and the put spreads may not hedge realized volatility if it spikes beyond implied levels priced at inception.
- Single-stock concentration. Both vehicles expose you to HIMS' business and regulatory risk alone. Any adverse news—clinical findings, reimbursement pressure, or competitive losses—affects the entire position with no diversification buffer. Thin trading volume in a newly launched fund can widen spreads and impair entry and exit pricing.
Bottom line
If you believe in HIMS' long-term growth and can wait for capital appreciation, the stock offers direct ownership with no synthetic-income layer or options complexity. Past performance does not predict future results, and the options structure introduces mechanics not present in equity ownership.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
